The Global report “Cell Culture Market is projected to reach USD 51.3 billion by 2028 from USD 27.9 billion in 2023, at a CAGR of 12.9% during the forecast period of 2023 to 2028. The growth of this market is majorly driven by the government support and funding for cell-based research, and emerging cell culture technologies for cell-based vaccines. On the other hand, the limitations in producing high-density cell cultures is restraining the growth of this market.

Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=559

The global cell culture market is expected to grow at a CAGR of 12.9% during the forecast period. The growth of this market is majorly driven by the increasing government support and funding for cell-based research, adoption of single-use technologies, emerging cell culture technologies for cell-based vaccines and incidence of infectious diseases. On the other hand, the expensive cell biology research is restraining the growth of this market.

DRIVER: Adoption of single-use technologies

Over the last few years, biopharmaceutical manufacturers have increasingly adopted single-use technologies (SUTs). These SUTs have helped comply with stringent regulations and control costs through multiple benefits. Some single-use bioreactors (SUBs) have low operating volume requirements; this allows for more flexibility in production volumes scaled up over time, depending on the demand. Also, SUTs reduce cross-contamination risk, facilitating rapid changeovers and multiple production batches. SUTs also require less space than multiple-use bioreactors, less capital investment, and less sterilization for storage. This reduces the overall operating and maintenance costs and the environmental impact of these operations. The advantages of SUTs have fueled their adoption in the biopharmaceutical sector, thus driving the growth of the overall market during the forecast period.

RESTRAINT: Limitations in producing high-density cell cultures

Although the adoption of advanced technologies such as microcarriers is increasing in high-density cell cultures, there are several limitations associated with their use, which makes the process of cell culture very laborious and expensive. Some of them are: Agitation is required in a stirred-tank bioreactor to make a homogenous cell culture system. Fluid turbulence damages cells and results in cell debris formation and low cell yield, thus increasing downstream processing costs. The number of microcarriers needs to be increased for higher culture density. This, however, leads to a higher degree of collisions (bead-to-bead or microcarrier-bound-cells to mechanical impeller), resulting in cell death and decreased cell yield.

OPPORTUNITY: Growth hotspots in emerging economies

Developing countries such as China, India, and other countries in the Asia Pacific are expected to offer significant growth opportunities for players operating in the market. The booming biopharmaceutical sector in these countries, increased risk of pandemics (such as swine flu and COVID-19), less-stringent regulatory guidelines, and the low manufacturing cost advantage are the major factors attracting market players to set up and expand their presence in these countries.

Request 10% Customization: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=559

Key Market Players:

The global cell culture market is a consolidated market, with Thermo Fisher Scientific (US), Danaher Corporation (US), Merck KGaA (Germany), Sartorius AG (Germany), Corning Incorporated (US) together accounting for ~70–75% of the global market.

Thermo Fisher Scientific (US) offers a complete and integrated portfolio of analytical instruments, reagents, consumables, and software services for research, discovery, analysis, diagnostics, and manufacturing. The company operates in four business segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products & Services. It offers cell culture products, such as consumables, instruments, and equipment, through three segments—Life Sciences Solutions, Specialty Diagnostics, and Laboratory Products & Services. Thermo Fisher Scientific operates in more than 150 countries across North America, Europe, Latin America, and Asia. Its premier brands include Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, and Patheon.

Danaher Corporation (US) manufactures medical, industrial, and commercial products and services. The company conducts its business through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment offers a wide range of products, such as analytical instruments, reagents, consumables, software, and services for diagnostics, research, analysis, manufacturing, and drug discovery. The company’s product portfolio includes single-use mixers, bioreactors, storage systems, and packaging solutions for pharmaceutical and biopharmaceutical companies. Danaher has manufacturing and distribution facilities in North America, Europe, Asia, South America, and Australia.

Merck KGaA (Germany) is one of the world’s leading pharmaceutical, life science, and chemical manufacturing companies. Merck operates through three business segments: Healthcare, Life Science, and Performance Materials. Merck provides cell culture products through all subsegments under its Life Science segment. Merck has a strong global geographic presence, with operations in Europe, North America, Asia Pacific, Latin America, and the Middle East & Africa.

This report categorizes the cell culture market to forecast revenue and analyze trends in each of the following submarkets:

By Product

• Consumables
• Equipment

By Consumables

• Sera, Media, and Reagents
• Vessels
• Accessories

By Equipment

• Supporting Equipment (filtration systems, cell counters, carbon dioxide incubators, centrifuges, autoclaves, microscopes, biosafety cabinets, other supporting equipment)
• Bioreactors (conventional bioreactors, single-use bioreactors)
• Storage Equipment (Refrigerators & freezers, Cryostorage systems)

The North America region catered the largest share of the cell culture market in 2022.

The growing regulatory approvals for and awareness of cell culture-based vaccines, rising investments in biopharmaceutical R&D coupled with various initiatives from the leading companies, and conferences and symposia that create awareness of the latest cell culture trends are the key factors driving the growth of the cell culture market in North America. Biopharmaceutical companies in North America focus on R&D activities to develop and commercialize novel drugs and therapies. Additionally, various initiatives from leading companies have accelerated growth in North America.

Key players in the cell culture market include Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), and Sartorius AG (Germany), Corning Incorporated (US).

Recent Developments:

• In October 2021, Thermo Fisher Scientific Inc. (US) launched the Gibco Cell Therapy Systems (CTS) NK-Xpander Medium, which supports the large-scale growth and culture of functional natural killer (NK) cells with or without the use of feeder cells.
• In September 2021, Cytiva expanded its manufacturing capacity for bioprocessing single-use consumables by launching 3 new manufacturing facilities in under ten months.

Report Link: ( Cell Culture Market )

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com

About MarketsandMarkets™

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are moulded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit MarketsandMarkets™ or follow us on Twitter, LinkedIn and Facebook.